Our Mission
Our mission is to offer superior products and services and provide exemplary customer service, with open communication and on-time delivery. We support entrepreneurial scientists and startups, diagnostic, pharmaceutical, and biotechnology companies with unparalleled experience and expertise that significantly shortens timelines and reduces costs.
History of SBH Sciences
SBH Sciences, Inc. was founded in 1997 with the sole purpose of producing mammalian-derived recombinant cytokines. Since 1999, we have expanded our activities to include cell-based bioassays, in-vitro anti-cancer and anti-inflammatory lead compound screening, and the development of ELISA kits and biomarker analyses. We have continued our growth through partnerships with several companies. Our product line now includes monoclonal antibodies and specific glycosyltransferase enzymes. We have increased our biomarker analysis capabilities by offering AlphaScreen/AlphaLISA, analytical HPLC, ELISA, ELLA, flow cytometry, HTRF®, Luminex, MSD, Peggy Sue / WES / Jess, SMCxPRO, IsoLight and real-time PCR platforms.
What We Do and Our Accomplishments
SBH Sciences, Inc. is a preclinical CRO (Contract Research Organization) offering extensive products and services including:
| 150 Analysis of over 150 biomarkers with expanded multiplex analysis capabilities. |
400+ Multiple cell-based disease models, including over 400 human cancer cell lines. |
| 27 Years SBH Sciences has provided services to over 300 biotechnology companies globally. |
350+ We offer over 350 cell-based assays for cytokine and chemokine activity. |
SBH Sciences is the world leader in cell-based assays for measuring the biological activity of cytokines and growth factors. Our proprietary processes have led to the development and commercialization of 30 highly purified recombinant cytokines, 33 monoclonal antibodies, and eight recombinant glycosyltransferase enzymes, as well as ELISA kits. We are currently the only commercial source for the native human GDF-15/MIC-1. Over our 27 years in business, SBH Sciences has provided services to over 300 biotechnology companies across the globe.
How SBH Sciences Can Help You
SBH Sciences streamlines the process of discovery and biopharmaceutical development by using our expertise efficiently and effectively. The multitude of products and services SBH Sciences offers can be customized to meet your specific needs. We are dedicated to providing your company with time- and cost- effective options to give your company a competitive advantage
SBH Leadership
Raphael Nir, PhD
President & Chief Scientific Officer
Dr. Raphael Nir has served as President and Chief Scientific Officer of SBH Sciences since co-founding the company in 1997. He started SBH Sciences to fulfill his dream of becoming a key player in the biotech arena, and to help companies develop drugs. Under his management, SBH Sciences has become a leading supplier of recombinant cytokines and a preferred discovery research service provider.
Raphael is an ambitious entrepreneur and has co-founded seven additional biotech and diagnostics companies: Karyopharm Therapeutics, SBH Diagnostics, Woodland Biosciences, Galectin Sciences, Alma Bio Therapeutics, Vuja De Sciences and NeuroDex. To fulfill his vision and help startup companies, he co-founded two additional companies; Sky Ventures and ABI-LAB; a 7-year old bioincubator located in Natick, MA, currently housing 45 biotechnology companies.
Prior to SBH Sciences formation, Raphael earned his Ph.D. in biotechnology as well as a M.S. in biochemistry, and a B.S. in chemistry from Tel-Aviv University. His postdoctoral research was at Schering Plough Research Institute where he later became a Senior Scientist/Associate Principal Scientist and developed innovative cell culture processes and solutions related to biological production. Additionally, he earned a M.S. in engineering management from New Jersey Institute of Technology (1997).
Tami Rashal, M.D., MBA
Chief Medical Officer
Tami Rashal, M.D., is the Chief Medical Officer of SBH Sciences, where she joined to support Dr. Raphael Nir’s vision to become a key player in the biotechnology industry. With over a decade of experience in clinical trial management and early-stage drug discovery, Dr. Rashal has successfully navigated multiple IND and NDA submissions, demonstrating her deep expertise in bringing novel therapies to patients.
Dr. Rashal is a seasoned hematologist-oncologist and entrepreneur with a proven track record of leading medical development companies at various stages of growth. Her experience also includes the successful management of Merlin, an AI-based clinical trial decision-making tool, which will play a key role in advancing SBH Sciences’ portfolio companies.
Dr. Rashal’s deep understanding of the oncology landscape, combined with her passion for advancing drug development and clinical research, will be invaluble to SBH Sciences and its Bioventure initiatives. Dr. Rashal earned her M.D. in Medicine from Semmelweis University and an MBA in Health Care Administration from Tel Aviv University. She completed her internal medicine training at Sheba Medical Center (Tel Hashomer) and her hematology-oncology fellowship at Sourasky Medical Center (Ichilov).
Adam Nir
Chief Diagnostic Officer
Adam Nir serves as the Chief Diagnostic Officer at SBH Sciences, bringing over a decade of expertise in biomarker analysis and diagnostic testing. He leads the biomarker department with precision, overseeing the seamless execution of complex, high-impact projects that drive scientific advancements. His extensive knowledge in ELISA development, multiplex analysis, and automated Western technology enables SBH Sciences to deliver cutting-edge, reproducible results that support breakthrough discoveries.
In 2024, Adam and his team provided expert biomarker analysis and diagnostic support to over 40 biotech companies, ensuring the highest standards of accuracy and reliability. Under his leadership, the laboratory adheres to Good Laboratory Practice (GLP) guidelines, maintaining the integrity and reproducibility of all data. Adam plays a pivotal role in strategic client support, offering comprehensive data analysis, optimizing project workflows, and providing scientific guidance that drives innovation.
Adam holds a Master of Arts in International Relations and a Master of Strategic Studies from Tel Aviv University (2013), along with dual Bachelor of Arts (B.A.) degrees in Biochemistry and Political Science from Brandeis University (2006).
Mentoring at SBH Sciences
For the last 27 years, SBH Sciences has supported and guided many start-up companies to value-creating milestones. SBH has assisted over 350 biotechnology, pharmaceuticals, and diagnostics companies world-wide. In addition, SBH is able to provide products and services for these companies to go through multiple phases of development, spanning from initial inception, to drug discovery, to target validation, and continuously supporting them through preIND/IDE work to once they reach clinical trials. In the last 10 years, SBH Sciences' co-founder, President, and CSO, Raphael Nir, PhD, co-founded and developed ABI-LAB, a Boston-based Accelerator and Bio-Incubator. ABI-LAB's mission is to support start-up companies and to accelerate their drug discovery programs. ABI-LAB has 60 state-of-the-art, affordable lab spaces with offices, as well as innovative pre-clinical services. Currently, 45 Biotechnology / Life Sciences companies reside at ABI-LAB and take advantage of the state-of-the-art shared equipment, private lab space, and many available services.
SBH has assembled six very experienced scientists / entrepreneurs, each with over 25 years’ experience covering a full range of capabilities in drug/device development, including:
- Analytical Method Design, Development, and Validation Planning
- Bioassay Design, Development, and Validation Planning
- Biomarker Selection and Analysis
- Cell Culture Method Development and Efficacy and Safety Use Strategy
- Companion and Targeted Diagnostic Planning and Development
- Drug Discovery & Development with Medicinal and Process Chemistry Strategy
- Drug Delivery and Formulation Planning for Preclinical and Clinical Projects
- Protein Production & Purification
- Grant Submission Strategy and Execution (e.g., SBIR/nonSBIR NIH, NSF, CDMRP)
- Preclinical and Clinical Protocol Development
- PreClinical/Clinical Development and Regulatory Submissions Design, Planning, Execution, including CMC; GLP; GMP; GCP strategy for preIND/IND enabling preclinical studies.
- Clinical Project Strategy, Documentation, Planning, Execution, and Support
We have been involved in many start-up companies as a Co-founders, Investors, Directors and C-Level managerial positions. We are committed to strengthening your organization by providing you with exemplary assistance to reduce mistakes, save money, and ensure you achieve your milestones faster. We guarantee to increase your probability of success! If your company is ready to go to the next level, SBH would be delighted to hear from you. Find out more about Mentorship at SBH.
Ventures at SBH
SBH Sciences is excited to expand its offerings and assist entrepreneurs with our new division, Ventures at SBH.
Ventures at SBH aims to incubate breakthrough scientific ideas and to support entrepreneurs in the early stages of research and development. SBH offers extensive lab space, equipment, scientific expertise, business development, grant submission assistance, networking opportunities, and early / seed-stage investments.
Expanding Services
SBH Sciences established two strategic partnerships expanding our services to cover the drug-discovery spectrum from in-vitro lead optimization through innovative animal modeling and companion diagnostics. In addition, SBH has partnered with ABI-LAB, a Boston-based Accelerator and Bio-Incubator, to offer 60 affordable lab spaces as well as innovative pre-clinical services. Find more details in our company presentation.
